The 10 most charitable people in America
Michael Bloomberg topped the list of the United States' biggest charitable donors, for the second year in a row, the Chronicle of Philanthropy announced Tuesday.
The billionaire's Bloomberg Philanthropies awarded significant grants to four historically Black medical schools: Howard University College of Medicine, Meharry Medical College, Morehouse School of Medicine, and Charles R. Drew University of Medicine & Science.
Bloomberg also gave $1 billion to his alma mater Johns Hopkins University. The grant money will make Johns Hopkins Medical School tuition free for students from families earning under $300,000 and will also increase financial aid for students pursuing degrees in nursing and public health.
While Bloomberg continues to give away much of his vast fortune, many of the most prominent billionaires in the U.S. failed to do the same. Just 19 of the richest Americans on the Forbes 400 made the Chronicle of Philanthropy's list of the country's 50 biggest donors. Bill Gates came in 18th place, while his ex-wife Melinda came in seventh place. Elon Musk, Jeff Bezos, Larry Ellison, and Larry Page all failed to make the rankings, despite being among the 10 wealthiest people in the country.
Some experts are concerned that the U.S. is in the midst of a crisis of generosity. In 2023, there was a 2.1% decline in charitable giving, according to the philanthropy research foundation Giving USA.
Even more dramatically, Vox reported that 20 million fewer households donated to charity in 2016 compared to 2000. Experts cite several reasons for this decrease, including declining participation in organized religion, increased anger over failures to address inequality, and a lack of disposable income among Gen Z and Millennials.
One demographic that continues to give to nonprofits, however, is the ultra-wealthy. This is particularly the case because wealthy individuals receive disproportionate benefits from the charitable tax deduction system. Experts caution, however, that relying on donations from the one percent isn't the most sustainable of money-raising strategies.
'This is a challenging time for many nonprofit organizations. They are confronting a diminishing share of Americans who donate, the effects of inflation, and, most recently, potentially significant cutbacks in government support,' said Maria Di Mento, who directs the Philanthropy 50, in a statement.
'The Philanthropy 50 demonstrates that even America's wealthiest donors, who generously back a range of different causes and organizations, will never be able to give enough money to replace the vital role of government funding or meet the needs of the nonprofit sector.'
Continue reading to learn more about the 10 most charitable individuals and couples in America.
For the latest news, Facebook, Twitter and Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Tesla's Optimus robot VP is leaving the company
The head of Tesla's Optimus humanoid robot program, Milan Kovac, is leaving the company. Kovac said Friday in a post on X that he "had to make the most difficult decision" of his life to leave. "I've been far away from home for too long, and will need to spend more time with family abroad," he wrote. Kovac said that was "the only reason" and that his support for Musk and Tesla is "ironclad." Kovac's departure was first reported Friday by Bloomberg News. The departure comes as Tesla CEO Elon Musk has claimed the company will have "thousands" of Optimus robots operating in its factories by the end of this year. "And we expect to scale Optimus up faster than any product, I think, in history, to get to millions of units per year as soon as possible," Musk said last month. Kovac worked at Tesla for nearly 10 years, with much of that time coming as a top engineer on the Autopilot team. He was tapped to help lead development of Optimus in 2022 and became a vice president overseeing the program in late 2024. "I'm driving the Optimus program (Tesla's humanoid robot) & all its engineering teams," Kovac previously wrote on his LinkedIn profile. "Separately, I'm also driving the engineering teams responsible for all the software foundations & infrastructure common between Optimus and Autopilot." Ashok Elluswamy, the vice president of Tesla's AI software division, will take over the Optimus project, according to Bloomberg. This story has been updated with information from Kovac's X post about his departure.
Bloomberg
2 hours ago
- Bloomberg
Investing Africa: 'Verdict Is Out' on African VC Funding
Enygma Ventures Founder Sarah Dusek says that Venture Capital funding in Africa could get a boost in 2025 with investors potentially diverting their capital away from more traditional destinations. She speaks to Bloomberg's Jennifer Zabasajja. (Source: Bloomberg)
Yahoo
2 hours ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
